Melanoma, Cancer research, Cancer, Internal medicine and Oncology are his primary areas of study. His work carried out in the field of Melanoma brings together such families of science as Immune checkpoint, Immunotherapy, Immunology, Disease and Programmed cell death. He interconnects Protein kinase B, Cell growth, Immune system and PI3K/AKT/mTOR pathway, PTEN in the investigation of issues within Cancer research.
His Cancer study combines topics from a wide range of disciplines, such as Mutation and Genome-wide association study. His research investigates the connection between Internal medicine and topics such as Surgery that intersect with issues in Cohort. His Oncology research incorporates elements of Clinical trial, Phases of clinical research, Retrospective cohort study, Genotype and Binimetinib.
Michael A. Davies mainly focuses on Melanoma, Cancer research, Internal medicine, Oncology and Cancer. His biological study deals with issues like Neuroblastoma RAS viral oncogene homolog, which deal with fields such as MEK inhibitor and Cutaneous melanoma. As a part of the same scientific family, Michael A. Davies mostly works in the field of Cancer research, focusing on PTEN and, on occasion, Tumor suppressor gene.
In the subject of general Internal medicine, his work in Metastatic melanoma, Dabrafenib and Clinical trial is often linked to In patient, thereby combining diverse domains of study. His work deals with themes such as Surgery, Phases of clinical research, Blockade, Nivolumab and Ipilimumab, which intersect with Oncology. His work in Cancer tackles topics such as Disease which are related to areas like Bioinformatics.
His primary scientific interests are in Melanoma, Cancer research, Internal medicine, Oncology and Cancer. The study incorporates disciplines such as Immune checkpoint, Immune system, Immunotherapy, Targeted therapy and Primary tumor in addition to Melanoma. His Cancer research research incorporates themes from Cell, Brain metastasis, Downregulation and upregulation, PI3K/AKT/mTOR pathway and In vivo.
His biological study spans a wide range of topics, including Trametinib and Cutaneous melanoma. His Oncology study combines topics in areas such as MEK inhibitor, Metastatic melanoma, Clinical trial and Systemic therapy. His Cancer research includes themes of Gene, DNA sequencing and Incidence.
Michael A. Davies mostly deals with Melanoma, Internal medicine, Oncology, Cancer research and Immune system. His Melanoma research incorporates elements of Cyclin-dependent kinase 4, Cyclin-dependent kinase 6, Cyclin-dependent kinase 2, Proportional hazards model and Hazard ratio. His Oncology research is multidisciplinary, incorporating elements of Cancer, Immunotherapy, Clinical trial, MEK inhibitor and Systemic therapy.
His work deals with themes such as Incidence, Microarray and Gene duplication, Gene, DNA sequencing, which intersect with Cancer. His Cancer research study combines topics from a wide range of disciplines, such as Cell growth, MAPK/ERK pathway, CD8, Metastasis and In vivo. His research investigates the link between Metastasis and topics such as Focal adhesion that cross with problems in Protein kinase B.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan;V. Gopalakrishnan;C. N. Spencer;C. N. Spencer;L. Nezi;A. Reuben.
A landscape of driver mutations in melanoma
Eran Hodis;Ian R. Watson;Ian R. Watson;Gregory V. Kryukov;Gregory V. Kryukov;Gregory V. Kryukov;Stefan T. Arold.
Genomic Classification of Cutaneous Melanoma
Rehan Akbani;Kadir C. Akdemir;B. Arman Aksoy;Monique Albert.
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Weiyi Peng;Jie Qing Chen;Chengwen Liu;Shruti Malu.
Cancer Discovery (2016)
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink;Sangeetha M. Reddy;Jianjun Gao;Shaojun Zhang.
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long;Uwe Trefzer;Michael A. Davies;Richard F. Kefford.
Lancet Oncology (2012)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Pei Ling Chen;Whijae Roh;Alexandre Reuben;Zachary A. Cooper.
Cancer Discovery (2016)
NRAS mutation status is an independent prognostic factor in metastatic melanoma.
John A. Jakob;Roland L. Bassett;Chaan S. Ng;Jonathan L. Curry.
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Caroline Robert;Jean J Grob;Daniil Stroyakovskiy;Boguslawa Karaszewska.
The New England Journal of Medicine (2019)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
Alexander M. Menzies;Alexander M. Menzies;D. B. Johnson;S. Ramanujam;V. G. Atkinson.
Annals of Oncology (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: